Managing diabetic retinopathy and diabetic macular edema (DME) in France involves a combination of targeted pharmacological agents, surgical procedures, and specialized diagnostic imaging. As highlighted in the France Diabetic Retinopathy Market Industry Report, clinical practices across French medical centers focus on preserving visual acuity and reducing microvascular complications through personalized, guidelines-based care protocols.
Anti-VEGF Therapies and Intravitreal Injections
Pharmacological intervention using vascular endothelial growth factor (VEGF) inhibitors represents the gold standard for treating vision-threatening diabetic macular edema:
-
Anti-VEGF Agents: Drugs such as ranibizumab, aflibercept, and faricimab are routinely administered via intravitreal injections in outpatient hospital settings and specialized eye clinics.
-
Mechanisms of Action: These therapies effectively inhibit abnormal vessel growth, diminish vascular permeability, and reduce retinal swelling, significantly improving visual outcomes for patients with proliferative diabetic retinopathy (PDR).
-
Dosing Regimens: French clinicians increasingly adopt treat-and-extend or pro re nata (PRN) dosing schedules to optimize therapeutic outcomes while minimizing treatment burden on patients and clinical infrastructure.
Corticosteroid Implants and Laser Photocoagulation
For patients showing insufficient response to anti-VEGF therapy or those with chronic edema, sustained-release intravitreal corticosteroid implants (such as dexamethasone or fluocinolone acetonide) offer long-term anti-inflammatory control. Furthermore, retinal laser photocoagulation—including pan-retinal photocoagulation (PRP) and focal grid laser treatments—remains a cornerstone intervention to induce regression of neovascularization and stabilize peripheral disease progression.
Surgical Interventions and Vitrectomy
In advanced stages characterized by persistent vitreous hemorrhage or tractional retinal detachment, vitreoretinal surgery becomes necessary. Micro-incisional vitrectomy surgery (MIVS) performed by experienced retinal specialists across university hospital centers (Centres Hospitaliers Universitaires - CHU) helps restore anatomical stability and prevent permanent blindness in high-risk patient populations.
